Note 1 - Summary of Significant Accounting Policies (Details Textual)		3 Months Ended		6 Months Ended
	Apr. 19, 2023	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Number of Tumor Samples		150,000		150,000
Number of Operating Segments				3
Cash and Cash Equivalents, at Carrying Value		$ 14,763,745		$ 14,763,745		$ 22,071,523
Long-term Debt, Total		0		0
Accounts Receivable, Allowance for Credit Loss, Current		0		0		0
Accounts Receivable, after Allowance for Credit Loss		430,849		430,849		331,196	$ 354,196
Contract with Customer, Liability		627,896		627,896		$ 602,073	$ 186,951
Research and Development Expense		29,367	$ 33,394	68,171	$ 101,612
Income Tax Expense (Benefit), Total				0
Unrecognized Tax Benefits, Ending Balance		$ 0		$ 0
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20